CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be presented as posters at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2024, taking place in Milan, Italy 5 – 8 June 2024.

马萨诸塞州康科德市（商业新闻短讯）--ClearB Therapeutics，Inc.，一家开发CLB-3000（一种旨在推动乙型肝炎功能性治疗的治疗性疫苗）的公司，今天宣布，两篇摘要将作为海报在2024年6月5日至8日于意大利米兰举行的2024年欧洲肝脏研究协会（EASL）国际肝脏大会（ILC）上发布。

In addition, one of the posters has been selected as a TOP presentation (see details below)..

此外，其中一张海报被选为顶级展示（详见下文）。。

“While we are progressing our therapeutic vaccine candidate, CLB-3000, in first in human trials, we are excited to share preclinical data on other approaches we are pursuing with the Hepatitis B community,” said Aileen Rubio, PhD, CEO of ClearB Therapeutics. “Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies.

ClearB Therapeutics首席执行官Aileen Rubio博士说：“虽然我们正在进行治疗性候选疫苗CLB-3000的首次人体试验，但我们很高兴与乙型肝炎社区分享我们正在寻求的其他方法的临床前数据。”。“慢性乙型肝炎（CHB）感染仍然是一个重大的全球卫生保健问题，需要有效的抗病毒和免疫调节疗法。

We believe that ClearB’s therapeutic vaccine and our other approaches could become an important component of combination treatment regimens.”.

我们相信ClearB的治疗性疫苗和我们的其他方法可能成为联合治疗方案的重要组成部分。”。

Abstract Number: SAT-339

摘要编号：SAT-339

Abstract Title: Sequential administration of siRNA with an mRNA encoding clearance profile associated variants of HBsAg exhibits significant antiviral activity in an AAV/HBV mouse model

摘要标题：用编码HBsAg清除谱相关变体的mRNA顺序施用siRNA在AAV/HBV小鼠模型中显示出显着的抗病毒活性

Date: Saturday, 8 June 2024

日期：2024年6月8日星期六

Time: 9:00 AM GMT+1

时间：格林威治时间上午9:00+1

Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics

主持人姓名：ClearB Therapeutics Aditi Deshpande博士

Abstract Number: TOP-353

摘要编号：TOP-353

Abstract Title: An mRNA vaccine exhibits anti-viral activity in a mouse model of persistent Hepatitis B infection

摘要标题：mRNA疫苗在持续性乙型肝炎感染的小鼠模型中表现出抗病毒活性

Date: Saturday, 8 June 2024

日期：2024年6月8日星期六

Time: 9:00 AM GMT+1

时间：格林威治时间上午9:00+1

Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics

主持人姓名：ClearB Therapeutics Aditi Deshpande博士

For more information regarding the abstracts at EASL 2024 please visit:

有关EASL 2024摘要的更多信息，请访问：

EASL Congress 2024 - OFFICIAL WEBSITE

2024年EASL大会-官方网站

About ClearB Therapeutics

关于ClearB Therapeutics

ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B.

ClearB Therapeutics于2017年由Morningside Ventures与Stephen Locarnini教授和澳大利亚墨尔本的维多利亚传染病参考实验室合作成立。ClearB正致力于开发治疗性疫苗，旨在推动乙型肝炎的功能性治愈。这项工作基于研究慢性乙型肝炎患者罕见事件感染解决方案的专有见解。

For more information, please visit https://clearbtherapeutics.com/..

有关更多信息，请访问https://clearbtherapeutics.com/..

About Morningside Ventures: Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific. In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products.

关于Morningside Ventures：Morningside由Chan家族于1986年成立，在北美、欧洲和亚太地区进行私人股本和风险投资。在生命科学领域，Morningside专门从事生物制药产品的早期（临床前通过人类概念验证）投资。

They partner with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. Morningside's focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and there is a plausible path forward in clinical development.

他们与学术创始人和企业家合作，建立世界级的公司，希望显着改善当今的医学状况，最终改善患者的生活。Morningside的重点是投资于优秀的生物医学研究，在那里已经收集了大量的知识，并且在临床开发方面有一条合理的道路。

Their mission is to contribute to making a meaningful, positive impact on the prevention or treatment of human disease, and believe that so long as this is achieved, commercial success will follow..

他们的使命是为预防或治疗人类疾病做出有意义的积极影响，并相信只要做到这一点，就会取得商业成功。。